Brielle Benyon | Authors


Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL

December 12, 2022

Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.

Lenvatinib/Pembrolizumab Benefit Maintained in Advanced Endometrial Cancer

September 11, 2022

After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.

Daratumumab Added to RVd Achieved MRD Negativity, PFS Improvement in Newly Diagnosed Myeloma

June 05, 2022

Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.